Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity

British Journal of Haematology

Volumn 116, Issue 2, 2002, Pages 278-290

  Epstein, Joshua ^a   Barlogie, Bart ^a   Johnson, Cherie L ^a   Yaccoby, Shmuel ^a   Pearse, Roger N ^b   Choi, Yongwon ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Division of Molecular Immunology Laboratory   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Bisphosphonates; Myeloma; Osteoclasts; RANKL; SCID hu

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ARTICLE; BONE MARROW; BONE MARROW CELL; CANCER GROWTH; CELL ACTIVITY; CELL INTERACTION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MYELOMA; MYELOMA CELL; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL;

ANIMALS; BONE MARROW CELLS; BONE TRANSPLANTATION; CELL DIVISION; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MICE; MICE, SCID; MULTIPLE MYELOMA; OSTEOCLASTS; TRANSPLANTATION, HETEROLOGOUS;

EID: 0036181668     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.2002.03257.x     Document Type: Article

References (42)

1. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
2. Soluble IL-6R alpha upregulated IL-6, MMP-1 and MMP-2 secretion in bone marrow stromal cells
3. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma
4. The critical role of interleukin-6, interleukin-1B and macrophage colony-stimulating factor in the pathogenesis of bone lesions in multiple myeloma
5. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs
6. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
7. Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma
8. Role of bone marrow stromal cells in the growth of human multiple myeloma
9. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B
10. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma
11. Ibandronate reduces osteolytic lesions but not tumor burden in a murine model of myeloma bone disease
12. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
13. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
14. Anti-myeloma activity of pamidronate in vivo
15. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
16. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts
17. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells
18. Characterization of bone marrow stromal cells from multiple myeloma
19. Inhibition of tooth eruption in the rat by a bisphosphonate
20. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone
21. Interleukin-6 prevents dexamethasone-induced myeloma cell death
22. Interleukin-6 gene expression in multiple myeloma: A characteristic of immature tumor cells
23. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
24. Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: A possible role for HGF in myeloma-associated osteolytic bone disease
25. Human myeloma cells promote the production of interleukin 6 by primary human osteoblasts
26. Interleukin-1 beta rather than lymphotoxin as the major bone resorbing activity in human multiple myeloma
27. Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
28. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
29. Comparison of interleukin-1 beta expression by in situ hybridization in monoclonal gammopathy of undetermined significance and multiple myeloma
30. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
31. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals
32. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and alpha (4) beta (1)-integrin enhances production of osteoclast-stimulating activity
33. The control of proliferation, survival and apoptosis in human multiple myeloma cells in vitro
34. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 5T2 multiple myeloma
35. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure
36. Bisphosphonates induce apoptosis in human myeloma cell lines: A novel anti-tumour activity
37. Production of parathyroid hormone-related protein by cultured human myeloma cells
38. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization
39. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption
40. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion
41. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host
42. Primary myeloma cells growing in SCID-hu mice - A model for studying the biology and treatment of myeloma and its manifestations